# BPA #36E79727A0002

Blanket Purchase Agreement for Pharmaceuticals with Travere Therapeutics

**Buyer:** Department of Veterans Affairs

**Award Amount:** $14,000,000.00
**Ceiling:** $14,000,000.00

**Awarded:** October 17, 2026
**Period of Performance:** Oct 17, 2026 - Oct 16, 2027

**Identifier:** 36E79727A0002
**NAICS:** 325412

This award is a blanket purchase agreement (BPA), an indefinite-delivery vehicle designed to efficiently procure pharmaceutical products. The recipient, Travere Therapeutics, Inc., is a pharmaceutical company known for developing treatments for rare and serious medical conditions, aligning closely with the contract's purpose. The contract facilitates a substantial procurement of pharmaceutical products critically supporting government health initiatives by ensuring a stable and timely supply of essential medicines. The BPA covers a one-year performance period beginning in the fall of 2026, allowing multiple orders and providing procurement flexibility over the term. The award builds upon a prior Federal Supply Schedule (FSS) agreement under Schedule 65 I B, which established non-competitive, pre-negotiated access to Travere’s drug portfolio, enabling expedited acquisition processes. Leveraging this existing vehicle, the current BPA enhances procurement efficiency without separate competitive solicitations. No subcontractors are associated with this contract, emphasizing a direct procurement approach. Overall, this agreement represents a significant government effort to maintain reliable access to vital pharmaceutical products, supporting public health objectives through streamlined acquisition methods.

### Description

BPA FOR FILSPARI

[View original record](https://www.usaspending.gov/award/CONT_IDV_36E79727A0002_3600)